Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for FREE ACCESS to this landmark database

CiteULike is a free service for managing and discovering scholarly references - click here to get started.

Sign In to gain access to subscriptions and/or personal tools.
Journal of Child Neurology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ng, Y.-t.
Right arrow Articles by Wu, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ng, Y.-t.
Right arrow Articles by Wu, T.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Drug Therapy in Juvenile Dermatomyositis: Follow-Up Study

Yu-tze Ng, MBBS

Department of Pediatrics

Robert A. Ouvrier, MD, BS, BSc(Med), FRACP

Department of Neurology, The New Children's Hospital, Westmead

Tammy Wu, MBBS

Royal North Shore Hospital, Saint Leonards, Australia

A series of 33 patients with juvenile dermatomyositis was reviewed in terms of their prognosis in relation to their drug therapy. This retrospective study was intended to help clarify the use of various therapies in this rare, heterogeneous disease from our hospital's experience in the last 24 years. The results confirmed that oral corticosteroids should remain the undisputed first line of treatment. For more refractory, chronic patients, the results suggest that azathioprine should be the favored drug of first choice (in addition to corticosteroids). There may be a role for cyclosporine as a "rescue" treatment, but this needs to be further defined. (J Child Neurol 1998;13:109-112).

Journal of Child Neurology, Vol. 13, No. 3, 109-112 (1998)
DOI: 10.1177/088307389801300303
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann Rheum DisHome page
I M Bronner, M F G van der Meulen, M de Visser, S Kalmijn, W J van Venrooij, A E Voskuyl, H J Dinant, W H J P Linssen, J H J Wokke, and J E Hoogendijk
Long-term outcome in polymyositis and dermatomyositis
Ann Rheum Dis, November 1, 2006; 65(11): 1456 - 1461.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. H. S. Choy and D. A. Isenberg
Treatment of dermatomyositis and polymyositis
Rheumatology, January 1, 2002; 41(1): 7 - 13.
[Abstract] [Full Text] [PDF]